Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GeoVax Labs ( (GOVX) ) has issued an announcement.
GeoVax Labs, Inc., a clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and solid tumors, is advancing its GEO-MVA mpox and smallpox vaccine toward an expedited Phase 3 trial, while progressing its Gedeptin gene-directed enzyme prodrug therapy in head and neck cancer and its GEO-CM04S1 next-generation COVID-19 vaccine. The company leverages a global IP estate and seeks partnerships and funding to support its orthopoxvirus, oncology and COVID-19 programs.
On May 18, 2026, GeoVax agreed a private placement with existing institutional investors, selling pre-funded and common warrants priced at-the-market under Nasdaq rules for gross proceeds of about $3 million and net proceeds of roughly $2.7 million. The offering, which closed May 19, 2026, provides working capital and general corporate funding, while imposing short-term restrictions on new equity issuance and variable-rate financings, shaping the company’s near-term capital-raising flexibility and warrant-driven potential dilution for shareholders.
The most recent analyst rating on (GOVX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GeoVax Labs stock, see the GOVX Stock Forecast page.
Spark’s Take on GOVX Stock
According to Spark, TipRanks’ AI Analyst, GOVX is a Underperform.
The score is driven primarily by very weak financial performance (large losses, sharp revenue decline, and substantial cash burn), with bearish price trends reinforcing downside risk. Valuation is not supportive due to negative earnings, and while recent financing improves liquidity, it also raises dilution risk.
To see Spark’s full report on GOVX stock, click here.
More about GeoVax Labs
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies targeting high-consequence infectious diseases and solid tumor cancers. Its lead programs include GEO-MVA, an MVA-based mpox and smallpox vaccine advancing toward a pivotal Phase 3 trial, the Gedeptin gene-directed enzyme prodrug therapy for head and neck cancer, and GEO-CM04S1, a next-generation COVID-19 vaccine for immunocompromised and other vulnerable patients.
The company maintains a global intellectual property portfolio supporting its infectious disease and oncology pipelines, while pursuing strategic partnerships and funding to advance its candidates through late-stage development. GeoVax’s programs are positioned to address biodefense needs, orthopoxvirus vaccine supply constraints and combination immuno-oncology strategies, underscoring its focus on both public health threats and cancer treatment innovation.
Average Trading Volume: 3,642,651
Technical Sentiment Signal: Sell
Current Market Cap: $4.27M
For a thorough assessment of GOVX stock, go to TipRanks’ Stock Analysis page.